Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) have both ...

MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...

There may be two distinct subtypes of multiple sclerosis, according to a new study led by scientists at University College ...

"In terms of association with climate, our results suggest a relationship between enhancing lesions and tropical nights, a variable indicating extreme temperatures, which had not been previously ...

For the first time, UCL researchers have used AI to identify two biologically distinct forms of multiple sclerosis ...

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

Please provide your email address to receive an email when new articles are posted on . Ocrelizumab reduced the number and size of MS-related cortical lesions. Data synthesis featuring a mix of ...

Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

MS is currently treated with 'disease-modifying' medicines (e.g. interferon beta, glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate). These medicines can ...